Evox Therapeutics Acquires Exosome AAV Technology and Intellectual Property

Utilizing our DeliverEX™ platform, we are engineering exosomes to deliver protein and nucleic acid-based therapeutics to treat life-threatening rare diseases. At Evox Therapeutics we are harnessing the natural targeting and delivery capabilities of exosomes to engineer an entirely novel class of biotherapeutics.

Article Date

This article is featured on another website.

Go to article